Soyoung Oh - Principal Scientist, Cancer Immunology, Research Biology

Soyoung Oh

Principal Scientist, Cancer Immunology, Research Biology

"The creativity, rigor, and collaborative nature of the science at Genentech make this a very special place. It’s inspiring to be part of a community that puts science and patients first."
Years at Genentech

I joined Genentech in 2016 as a Senior Scientific Researcher in the Cancer Immunology department, and in 2020, started my own group as a Scientist in the department. During my time at Genentech, I have continued to explore my long-standing interest in T cell biology by studying how key regulatory pathways and T cell-intrinsic properties influence the outcome of a T cell response. From identifying the critical role dendritic cells play in the PD-1/PD-L1 regulatory axis, to employing novel CRISPR-engineering technologies in the development of T cell therapies, Genentech has provided a dynamic, creative, and collaborative environment to pursue incredible science with the goal of bringing new therapeutics to patients in need.

Featured Publication

PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer

Nature Cancer, 2020

Oh, S.A., Wu, DC., Cheung, J. et al.